This brand name is authorized in New Zealand
The drug BUCCALINE contains a combination of these active pharmaceutical ingredients (APIs):
1
Haemophilus influenzae type B 1500 million organisms (inactivated "germs")
UNII F2TW0N64FI - HAEMOPHILUS INFLUENZAE TYPE B
|
Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease. |
2
Pneumococcus I,II,III 1000 million organisms (inactivated "germs")
UNII BT6U234YR2 - STREPTOCOCCUS PNEUMONIAE
|
|
3
Staphylococcus aureus 1000 million organisms (inactivated "germs")
UNII O478WX4004 - STAPHYLOCOCCUS AUREUS
|
|
4
Streptococcus agalactiae 1000 million organisms (inactivated "germs")
UNII 2B3763S671 - STREPTOCOCCUS AGALACTIAE
|
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
J07AX | Other bacterial vaccines | J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 449 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.